[1]马彦娥,苏虎艳,王倩如,等.非小细胞肺癌组织中miR-30a和CD73的表达水平与预后相关性分析[J].现代检验医学杂志,2022,37(03):73-78.[doi:10.3969/j.issn.1671-7414.2021.03.015]
　MA Yan-e,SU Hu-yan,WANG Qian-ru,et al.Correlation Analysis of Tissue miR-30a and CD73 Expression Levels and Prognosis in Non-small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2022,37(03):73-78.[doi:10.3969/j.issn.1671-7414.2021.03.015]
点击复制

非小细胞肺癌组织中miR-30a和CD73的表达水平与预后相关性分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年03期
页码:
73-78
栏目:
论　著
出版日期:
2022-05-15

文章信息/Info

Title:
Correlation Analysis of Tissue miR-30a and CD73 Expression Levels and Prognosis in Non-small Cell Lung Cancer
文章编号:
1671-7414（2022）03-073-06
作者:
马彦娥; 苏虎艳; 王倩如; 郝光军
（榆林市第一医院肿瘤诊疗中心，陕西榆林 719000）
Author(s):
MA Yan-e;  SU Hu-yan;  WANG Qian-ru;  HAO Guang-jun
（ Center of Cancer Diagnosis and Treatment, the First Hospital of Yulin City, Shaanxi Yulin 719000,China）
关键词:
非小细胞肺癌; 微小核糖核酸-30a; 胞外5’- 核苷酸酶; 生存分析
分类号:
R734.2；R730.43
DOI:
10.3969/j.issn.1671-7414.2021.03.015
文献标志码:
A
摘要:
目的　探究微小核糖核酸（ micro RNA, miR）-30a，胞外 -5’核苷酸酶（ ecto-5’-nucleotidase, CD73）在非小细胞肺癌（ non-small cell lung cancer，NSCLC）组织中的表达及其预后相关性。方法　选取 2015年 8月～ 2019年 12月于榆林市第一医院术后病理检查证实为 NSCLC患者癌组织 120例为研究组， 50例正常癌旁组织（距离癌组织 5cm以上）为对照组，采用实时荧光定量 PCR（qRT-PCR）技术检测组织标本中 miR-30a相对表达量，免疫组织化学法检测 CD73的表达情况，分析 miR-30a，CD73表达水平与 NSCLC患者临床病理参数及生存时间之间的关系，多因素 COX回归分析影响 NSCLC患者预后的危险因素。结果　miR-30a在 NSCLC癌组织中的表达水平（ 1.17±0.21）明显低于正常癌旁组织（ 1.62±0.48），差异有统计学意义（ t=8.521，P=0.000）；CD73在 NSCLC癌组织及癌旁正常组织中的阳性表达率分别为 63.33%（76/120）和 32.00%（16/50），差异有统计学意义（ χ2=13.955，P=0.000）；miR-30a高表达组 NSCLC患者一年累积生存率（ 86.89%）明显高于低表达组（ 59.32%）（Log Rank χ2=11.652，P=0.000）；CD73高表达组 NSCLC患者一年累积生存率（ 58.82%）明显低于低表达组（ 92.31%）（Log Rank χ2=16.894，P=0.000）；多因素 COX回归分析，结果显示分化程度低（ HR=1.677，95%CI：1.092～ 2.576），发生淋巴结转移（HR=1.574，95%CI： 1.043～ 2.376），miR-30a低表达（ HR=1.479，95%CI：1.027～ 2.130），CD73高表达（ HR=1.501，95%CI：1.059～ 2.128）是影响 NSCLC患者预后不良的危险因素。结论　NSCLC癌组织中， miR-30a表达下调， CD73表达上调，二者水平异常表达可能与 NSCLC的发生发展有关，低 miR-30a和高 CD73与患者预后不良有关。
Abstract:
Objective　To investigate the expression of microRNA (miR)-30a and ecto-5’-nucleotidase (CD73) in non-small cell lung cancer (NSCLC) tissues and their prognostic correlation. Methods　From August 2015 to December 2019, 120 cases of cancerous tissues from NSCLC patients confirmed by postoperative pathological examination in the First Hospital of Yulin City were selected as the study group, and 50 cases of normal adjacent tissues (more than 5cm away from cancer tissue) were selected as the control group.The relative expression of miR-30a in tissue samples was detected with quantitative real-time PCR (qRTPCR) technology,the expression of CD73 was detected with immunohistochemical method,the relationship between the expression levels of miR-30a and CD73 and the clinicopathological parameters and survival time of NSCLC patients was analyzed, the risk factors affecting the prognosis of NSCLC patients were analyzed with multivariate COX regression. Results　 The expression level of miR-30a in NSCLC cancer tissues (1.17±0.21) was significantly lower than that of normal adjacent tissues (1.62±0.48), and the difference was statistically significant (t=8.521, P=0.000). The positive expression rate of CD73 in NSCLC cancer tissues and normal adjacent tissues was 63.33% (76/120) and 32.00% (16/50), respectively, and the difference was statistically significant (χ2=13.955, P=0.000).The one-year cumulative survival rate of NSCLC patients in the miR-30a high expression group (86.89%) was significantly higher than that in the low expression group (59.32%)(Log Rankχ2=11.652, P=0.000). The one-year cumulative survival rate of NSCLC patients in the CD73 high expression group (58.82%) was significantly lower than that in the low expression group(92.31%)(Log Rankχ2=16.894, P=0.000).Multivariate COX regression analysis showed low differentiation (HR=1.677, 95%CI: 1.092~2.576), lymph node metastasis(HR=1.574,95%CI:1.043 ～ 2.376), and low miR-30a expression (HR=1.479, 95%CI:1.027 ～ 2.130) and high CD73 expression (HR=1.501, 95%CI: 1.059 ～ 2.128) were risk factors affecting the poor prognosis of NSCLC patients. Conclusion　In NSCLC cancer tissues, the expression of miR-30a was down-regulated and the expression of CD73 was up-regulated. The abnormal expression of both levels would be related to the occurrence and development of NSCLC. Low miR-30a and high CD73 were related to the poor prognosis of patients.

参考文献/References:

[1] DUMA N, SANTANA-DAVILA R, MOLINA J R. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment[J]. Mayo Clin Proc, 2019, 94(8):1623-1640.
[2] LE Xiuning, NILSSON M, GOLDMAN J,et al. Dual EGFR-VEGF pathway inhibition: A promising strategy for patients with EGFR-mutant NSCLC [J]. J Thorac Oncol, 2021, 16(2):205-215.
[3] LEE S S, CHEAH Y K. The interplay between microRNAs and cellular components of tumour microenvironment (TME) on non-small-cell lung cancer (NSCLC) progression [J]. J Immunol Res, 2019, 2019(1):1-12.
[4] YU Junfang, SUI Xiaojun. MiRNA-30 play an important role in non-small cell lung cancer (NSCLC) [J]. Clin Lab, 2020, 66(4):190712.
[5] O’CONNOR R A, CHAUHAN V, MATHIESON L, et al.T cells drive negative feedback mechanisms in cancer associated fibroblasts, promoting expression of co-inhibitory ligands, CD73 and IL-27 in non-small cell lung cancer [J].Oncoimmunology,2021,10(1):1940675.
[6] GIATROMANOLAKI A, KOUROUPI M, POULILIOU S ,et al.Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways[J]. Life Sci,2020,259:118389.
[7] JONNA S, SUBRAMANIAM D S. Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update[J].Discov Med,2019,27(148):167-170.
[8] YI Ming, XU Linping, JIAO Ying,et al. The role of cancer-derived microRNAs in cancer immune escape[J].J Hematol Oncol J Hematol Oncol, 2020, 13(1):25.
[9] 黄刚, 陈霏, 肇玉博, 等. 非小细胞肺癌患者血浆 miRNA-145 和miRNA-221 表达与临床特征及术后 复发的相关性研究[J]. 现代检验医学杂志, 2019, 34(4):40-44. HUANG Gang, CHEN Fei, ZHAO Yubo, et al. Study on the correlation between the expression of microRNA145 and microRNA221 in plasma and clinical characteristics and postoperative recurrence in patients with non-small cell lung cancer [J]. Journal of Modern Laboratory Medicine, 2019, 34(4):40-44.
[10] SHEERVALILOU R, LOTFI H, SHIRVALILOO M, et al. Circulating miR-10b, miR-1 and miR-30a expression profiles in lung cancer: possible correlation with clinico-pathologic characteristics and lung cancer detection [J]. Int J Mol Cell Med, 2019, 8(2):118-129.
[11] PARK G, SON B, KANG J,et al. LDR-induced miR- 30a and miR-30b target the PAI-1 pathway to control adverse effects of NSCLC radiotherapy [J]. Mol Ther, 2019, 27(2):342-354.
[12] YU Ting, GONG Li, LI Wei,et al. MiR-30a suppresses metastasis of gastric adenocarcinoma via targeting FAPα[J]. Cancer Biomark, 2020, 27(4):471-484.
[13] WU Geting, XIE Bin, LU Can, et al. MicroRNA-30a attenuates TGF-β1-induced activation of pulmonary fibroblast cell by targeting FAP-α [J]. J Cell Mol Med, 2020, 24(6):3745-3750.
[14] ZHOU Liangjing, JIA Shengnan, DING Guoping, et al. Down-regulation of miR-30a-5p is associated with poor prognosis and promotes chemoresistance of gemcitabine in pancreatic ductal adenocarcinoma [J]. J Cancer, 2019, 10(21):5031-5040.
[15] LIN Xiao, LAI Xiaojing, FENG Wei,et al. MiR- 30a sensitized lung cancer against neoadjuvant chemotherapy by depressing autophagy [J]. Jpn J Clin Oncol, 2021, 51(5):675-684.
[16] PASSARELLI A, AIETA M, SGAMBATO A,et al.Targeting immunometabolism mediated by CD73 pathway in EGFR-mutated non-small cell lung cancer: a new hope for overcoming immune resistance[J].Front Immunol,2020,11:1479.
[17] JIN Rui, LIU Liang, XING Yun,et al. Dual mechanisms of novel CD73-targeted antibody and antibodydrug conjugate in inhibiting lung tumor growth and promoting antitumor immune-effector function[J].Mol Cancer Ther,2020,9(11):2340-2352.
[18] DIETRICH F, FIGUEIR? F, FILIPPI-CHIELA E C, et al. Ecto-5’-nucleotidase/CD73 contributes to the radiosensitivity of T24 human bladder cancer cell line[J].J Cancer Res Clin Oncol,2018,144(3):469-482
[19] 沈海涛, 焦荣红, 陆志成, 等. 原发性肝癌患者外周 血CD39+,CD73+ 调节性T 细胞和然杀伤(NK) 细胞 的表达及其与肝损伤的相关性[J]. 现代检验医学杂 志, 2019, 34(1):10-13. SHEN Haitao, JIAO Ronghong, LU Zhicheng, et al. Correlation between the expression of peripheral blood CD39+ and CD73+ in regulatory T cells and nature kill cell in patients with hepatocellular carcinoma and liver injury [J]. Journal of Modern Laboratory Medicine, 2019, 34(1):10-13.
[20] 高锋, 陈丽秀, 朱于娟, 等. CD73 与调节性T 细胞 在非小细胞肺癌中的表达及其临床意义[J]. 临床肺 科杂志, 2020, 25(6):902-907. GAO Feng, CHEN Lixiu, ZHU Yujuan, et al. Expression and clinical significance of CD73 and regulator T cells in non-small cell lung cancer[J]. Journal of Clinical Pulmonary Medicine, 2020, 25(6):902-907.
[21] ZHU Jianjie, ZENG Yuanyuan, LI Wei,et al. CD73/ NT5E is a target of miR-30a-5p and plays an important role in the pathogenesis of non-small cell lung cancer[J].Mol Cancer,2017,16(1):34.

相似文献/References:

[1]张 蕾,任亚女,曾婷婷,等.晚期非小细胞肺癌患者血液实验指标和病理分期等因素对生存时间的影响分析[J].现代检验医学杂志,2016,31(02):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
　ZHANG Lei,REN Ya-n,ZENG Ting-ting,et al.Analysis of Prognosis Related Factors in Patients with Advanced Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(03):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
[2]薛鸿涛,任 敏,李长彬.非小细胞肺癌患者放疗前后血清TSGF和CRP的变化及其临床意义[J].现代检验医学杂志,2016,31(02):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
　XUE Hong-tao,REN Min,LI Chang-bin.Impact and Clinical Significance of Radiotherapy on Serum TSGF and CRP in Patients with Non Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(03):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
[3]王京伟,李 艳,童永清,等.湖北地区非小细胞肺癌EGFR 基因突变及其意义的研究[J].现代检验医学杂志,2016,31(03):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
　WANG Jing-wei,LI Yan,TONG Yong-qing,et al.Detection of Epidermal Growth Factor Receptor(EGFR) Mutations and the Significance in Patients with Non-small Cell Lung Cancer(NSCLC)of Hubei Province[J].Journal of Modern Laboratory Medicine,2016,31(03):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
[4]易甲其,范艳平,周宁加,等.血清PTX-3，CYFRA21-1和TPS在非小细胞肺癌中的变化及临床意义[J].现代检验医学杂志,2015,30(05):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
　YI Jia-qi,FAN Yan-ping,ZHOU Ning-jia,et al.Changes and Clinical Significance of Serum PTX-3， CYFRA21-1，TPS in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2015,30(03):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
[5]钱忠萍,凌 晨,祁松楠,等.围非小细胞肺癌手术期T细胞含量变化的研究[J].现代检验医学杂志,2016,31(05):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
　QIAN Zhong-ping,LING Chen,QI Song-nan,et al.Content Variation of T Cells in Perioperative Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(03):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
[6]黎谢梦丹,罗 凯,吴顺芳,等.华南地区非小细胞肺癌患者肿瘤组织EGFR,ALK和ROS1基因突变分析[J].现代检验医学杂志,2017,32(05):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
　LIXIE Meng-dan,LUO Kai,WU Shun-fang,et al.Mutation Analysis of EGFR,ALK and ROS1 in Tumor Tissues of Patients with Non-Small Cell Lung Cancer in South of China[J].Journal of Modern Laboratory Medicine,2017,32(03):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
[7]李小龙,白巧艳,陆婉玲.老年非小细胞肺癌患者低分割放疗对凝血功能的影响[J].现代检验医学杂志,2018,33(05):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
　LI Xiao-long,BAI Qiao-yan,LU Wan-ling.Influence of Hypofractionated High-Dose Radiotherapy on Coagulation Function in Elderly Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(03):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
[8]郭 华a,齐宗利a,张海祥b,等.非小细胞肺癌组织EGFR/ALK/ROS1基因联合检测的临床意义[J].现代检验医学杂志,2018,33(06):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
　GUO Huaa,QI Zong-lia,ZHANG Hai-xiangb,et al.Clinical Significance of Combined Detection of EGFR/ALK/ROS1 Genes in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(03):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
[9]黄 刚,陈 霏,肇玉博,等.非小细胞肺癌患者血浆miRNA-145和miRNA-221表达与临床特征及术后复发的相关性研究[J].现代检验医学杂志,2019,34(04):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
　HUANG Gang,CHEN Fei,ZHAO Yu-bo,et al.Study on the Correlation between the Expression of MicroRNA145 and MicroRNA221 in Plasma and Clinical Characteristics and Postoperative Recurrence in Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2019,34(03):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
[10]蒋玲丽,黄中强,王雪亮,等.表皮生长因子受体（EGFR）基因突变检测质控品制备及应用[J].现代检验医学杂志,2020,35(02):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]
　JIANG Ling-li,HUANG Zhong-qiang,WANG Xue-liang,et al.Development and Application of Quality Control Materials for EpidermalGrowth Factor Receptor （EGFR）Mutation Determination[J].Journal of Modern Laboratory Medicine,2020,35(03):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]

备注/Memo

备注/Memo:
基金项目：榆林市科技计划项目（项目编号【2019】185 号-41）：miR-376a 调控TRIM22-CDC14A 参与小细胞肺癌顺铂耐药性的研究。
作者简介：马彦娥（1986-）, 女, 硕士研究生，主治医师，从事肺癌靶向治疗方面的研究，E-mail:m18791296328@163.com。
通讯作者：苏虎艳（1989-），女，硕士研究生，主治医师，主要从事肺癌靶向治疗方面的研究。
更新日期/Last Update: 1900-01-01